Organization | Changhai Hospital

Changhai Hospital Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4

Founded: Shanghai China (1979)

Organization Overview

First Clinical Trial

2005

NCT00713557

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2022

Timeline

NOW

Now

Alternative names

11.Changhai Hospital | Changhai Hospital | Changhai Hospital Shanghai | Changhai Hospital, Shanghai, China | Changhai Hospital,Shanghai,China | Changhai houspital | Chanhai hospital | Cz Li | Department of Hematology, Changhai Hospital | Department of thyroid and breast surgery, Changhai Hospital | Guo ShiWei | Kai-Yang Lv | Neurology Department of Changhai Hospital | Neurosurgical Department of Changhai Hospital | Yiqi Du | Zhuan Liao

Active Ingredients

Drugs in Phase 4 Trials (18)

acetylsalicylic acid (aspirin) (2 trials)

calcium carbonate (1 trial)

clopidogrel (plavix) (1 trial)

cytarabine (cytosar-u) (3 trials)

dyclonine (sucrets) (1 trial)

fludarabine (fludara) (4 trials)

flurbiprofen (ansaid) (1 trial)

glycerin (1 trial)

indomethacin (indocin) (2 trials)

interferon alpha-2b (Intron-A) (1 trial)

polyethylene glycol (4 trials)

qishen (1 trial)

remifentanil (ultiva) (5 trials)

ribavirin (virazole) (1 trial)

somatostatin (2 trials)

sucralfate (carafate) (1 trial)

terlipressin (1 trial)

tetraprenylacetone (1 trial)

Drugs in Phase 3 Trials (26)

antigen pulsed dendritic cells (1 trial)

bivalirudin (angiomax) (1 trial)

busulfan (myleran) (2 trials)

carboplatin (paraplatin) (2 trials)

cisplatin (platinol) (1 trial)

cladribine (leustatin) (2 trials)

epirubicin (ellence) (2 trials)

esomeprazole (nexium) (1 trial)

ferric citrate (auryxia) (1 trial)

fluorouracil (efudex) (2 trials)

gefitinib (iressa) (2 trials)

gelatin (2 trials)

gemcitabine (gemzar) (7 trials)

heparin (liquaemin) (1 trial)

isodihydroperparine (1 trial)

lactobacillus delbrueckii (1 trial)

leucovorin (2 trials)

lipiodol (2 trials)

lxi-15028 (2 trials)

oxaliplatin (eloxatin) (3 trials)

paclitaxel (taxol) (5 trials)

pronase (2 trials)

ranibizumab (lucentis) (1 trial)

scopolamine (transderm scop) (1 trial)

sevelamer (renagel) (1 trial)

thalidomide (Thalomid) (1 trial)

Drugs in Phase 2 Trials (26)

anti-kras g12v mtcr (1 trial)

cinobufacin (1 trial)

cyclophosphamide (cytoxan) (2 trials)

cytotoxic t cells (1 trial)

dendritic cells (1 trial)

doxorubicin (Doxil) (1 trial)

erlotinib (tarceva) (1 trial)

genakumab (1 trial)

gimeracil (2 trials)

glumetinib (1 trial)

irinotecan (Camptosar) (1 trial)

lenalidomide (revlimid) (1 trial)

oteracil (2 trials)

pd-l1/ctla4 bsab (1 trial)

pemetrexed (alimta) (1 trial)

prednisone (meticorten) (1 trial)

psma car-t cell (1 trial)

simethicone (2 trials)

sodium chloride (2 trials)

sorafenib (nexavar) (1 trial)

tegafur (2 trials)

tislelizumab (1 trial)

ulinastatin (1 trial)

umbilical cord mesenchymal stem cells (2 trials)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (6)

car-cldn18.2 t-cells (1 trial)

cea car-t cells (1 trial)

dental pulp mesenchymal stem cells (1 trial)

hyaluronic acid (1 trial)

personalized neoantigen vaccine (1 trial)

stem cells from human exfoliated teeth (1 trial)

Drugs in Other Trials (25)

acetic acid (vosol) (1 trial)

alteplase (Activase) (1 trial)

autologous dendritic cells electroporated with wt1 mrna (1 trial)

azathioprine (imuran) (1 trial)

buprenorphine (1 trial)

car-cld18 t cells (1 trial)

dexmedetomidine (precedex) (4 trials)

diazepam (valium) (1 trial)

fentanyl (Innovar) (3 trials)

interferon alpha-2a (roferon-a) (1 trial)

jianpixiaozhong (1 trial)

Lactobacillus acidophilus (1 trial)

leflunomide (arava) (1 trial)

meperidine (demerol) (1 trial)

metamizole (Novalgin) (1 trial)

midazolam (versed) (2 trials)

mitomycin (mutamycin) (1 trial)

morphine (2 trials)

oxycodone (oxycontin) (1 trial)

pinaverium bromide (1 trial)

propofol (diprivan) (2 trials)

telbivudine (tyzeka) (1 trial)

tirofiban (aggrastat) (1 trial)

tramadol (Ultram) (1 trial)

vitamin c (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acute Disease (Phase 4)

Acute Kidney Injury (Phase 4)

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 2)

Adenoma (Phase 4)

Aneurysm (Phase 3)

Bile Duct Diseases (Phase 3)

Brain Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Calculi (Phase 4)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Pancreatic Ductal (Phase 2)

Carcinoma, Renal Cell (Phase 2)

Cataract (Phase 3)

Colorectal Neoplasms (Phase 3)

Congenital Abnormalities (Phase 3)

Coronary Artery Disease (Phase 4)

Diabetes Mellitus, Type 1 (Phase 1)

Diarrhea (Phase 3)

Edema (Phase 3)

Esophagitis (Phase 3)

Fibrosis (Phase 4)

Gastritis (Phase 4)

Gastroesophageal Reflux (Phase 3)

Gastrointestinal Hemorrhage (Phase 4)

Heart Diseases (Phase 4)

Hemorrhage (Phase 4)

Herpangina (Phase 4)

Hyperphosphatemia (Phase 3)

Intracranial Aneurysm (Phase 3)

Kidney Diseases (Phase 3)

Kidney Failure, Chronic (Phase 3)

Leukemia (Phase 4)

Leukemia, Myeloid (Phase 4)

Leukemia, Myeloid, Acute (Phase 4)

Liver Cirrhosis (Phase 4)

Liver Neoplasms (Phase 2)

Lung Injury (Phase 2)

Lung Neoplasms (Phase 3)

Macular Edema (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasm Metastasis (Phase 2)

Neoplasms, Second Primary (Phase 2)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Overweight (Phase 4)

Pancreatic Diseases (Phase 3)

Pancreatic Neoplasms (Phase 2)

Pancreatitis (Phase 4)

Prostatic Neoplasms (Phase 2)

Radiculopathy (Phase 4)

Recurrence (Phase 2)

Renal Insufficiency, Chronic (Phase 3)

Respiratory Aspiration (Phase 2)

Stomach Diseases (Phase 2)

Subarachnoid Hemorrhage (Phase 3)

Thrombosis (Phase 3)

Triple Negative Breast Neoplasms (Phase 3)

Vascular Malformations (Phase 3)

Wounds and Injuries (Phase 2)

Overview

Highest Phase: Phase 4
# of Trials: 74
# of Trial APIs: 101